Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMJGleeson Regulatory News (GLE)

Share Price Information for MJGleeson (GLE)

Share Price is delayed by 15 minutes
Get Live Data
250.50    5.50 (2.24%)
Bid:
250.00
Ask:
251.00
Spread: 1.00 (0.40%)
Market Cap: £146.13m
GLE Live PriceLast checked at - London Stock Exchange

Intraday MJGleeson Share Chart

AGM Trading Update

15 Nov 2024 07:00

RNS Number : 3422M
MJ Gleeson PLC
15 November 2024
 

MJ Gleeson plc  (GLE.L)

 

AGM Trading Update

15 November 2024

MJ Gleeson plc, the low-cost housebuilder and land promoter, is issuing the following update ahead of its Annual General Meeting which is being held later today.

As previously indicated, and for the reasons set out below, the results for the financial year will be more weighted to the second half than usual. The Board continues to expect that the results for the year will be in line with current market expectations1.

Gleeson Homes

As anticipated, the lack of conviction in the market continued through the Autumn. Last week's base rate reduction was welcome and is expected to bolster buyer confidence into the important Spring selling season.

Net reservation rates for the period 1 July to 1 November 2024 increased to 0.56 per site per week (0.47 excluding bulk reservations), from the 0.45 per site (0.41 excluding bulk reservations) during the same period last year.

Gleeson Homes continues to experience margin pressure as a result of the use of higher sales incentives, the impact of multi-unit sales, increased build costs and limited relief from increasing selling prices.

Gleeson Homes has commenced its programme of new site openings, having already opened 7 new sales sites this financial year. The division expects to open a total of 27 sales sites during the year (FY2024: 4 sales sites opened), but will be selling overall on a lower average number of sites than last year, with fewer sites in H1 than H2. Gleeson Homes will continue the positive momentum of site openings from FY2026 targeting a net 10 new sales sites per year.

As the wider market improves, we remain confident in Gleeson Homes' ability to fulfil this ambitious programme of site openings which will drive the exciting sector-leading growth planned for FY2026 and beyond.

Gleeson Land

Gleeson Land continues to promote several exciting opportunities. The prospective reform of the National Planning Policy Framework is expected to beneficially impact the timing of certain sites. 

Strong demand for consented land from large and medium-sized developers continues to give the Board confidence that Gleeson Land will deliver a full year result materially ahead of last year, with a number of significant sales expected to be completed in H2.

A Trading Update for the 6 months to 31 December 2024 will be issued on 14 January 2025.

 

1 Analyst consensus for FY2025 can be found at: https://www.mjgleesonplc.com/investors/analyst-coverage/

 

 

 

The information contained within this announcement was previously deemed by the Company to constitute inside information as stipulated by Market Abuse Regulation (EU) No 596/2014 ("EU MAR") and the retained UK law version of EU MAR pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019 (SI 2019/310) ("UK MAR"). With the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain. For the purposes of UK MAR, the person responsible for arranging for the release of this information on behalf of MJ Gleeson plc is Stefan Allanson, Chief Financial Officer

LEI: 21380064K7N2W7FD6434

Enquiries:

 

MJ Gleeson plc

 +44 1142 612 900

Graham Prothero Chief Executive Officer

Stefan Allanson Chief Financial Officer

Hudson Sandler

+44 207 796 4133 / gleeson@hudsonsandler.com

Mark Garraway

Harry Griffiths

 

Singer Capital Markets

+44 20 7496 3000

Shaun Dobson

Charles Leigh-Pemberton

Investec

+44 207 597 4000

Ben Griffiths

Tom Brookhouse

  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKQBBDBDBKDD
Date   Source Headline
2nd Jun 20267:00 amRNSBoard Committee Changes
7th May 20264:36 pmRNSDirector/PDMR Shareholding
7th May 20262:49 pmRNSDirector/PDMR Shareholding
1st May 20267:00 amRNSTrading Update
23rd Apr 20267:00 amRNSNotice of Trading Updates and FY2026 Results
14th Apr 20269:34 amRNSDirector/PDMR Shareholding
14th Apr 20269:33 amRNSDirector/PDMR Shareholding
6th Mar 20263:19 pmRNSDirector/PDMR Shareholding
2nd Mar 20264:04 pmRNSHolding(s) in Company
11th Feb 20267:00 amRNSResults for the half year ended 31 December 2025
9th Feb 202610:47 amRNSDirector/PDMR Shareholding
9th Feb 20267:00 amRNS-RPresentation of HY Results on Engage Investor
16th Jan 20267:00 amRNSTrading Update and Notice of Results
6th Jan 20264:40 pmRNSDirector/PDMR Shareholding
9th Dec 202511:31 amRNSDirector/PDMR Shareholding
25th Nov 20251:01 pmRNSDirector/PDMR Shareholding
20th Nov 20253:25 pmRNSHolding(s) in Company
14th Nov 20252:46 pmRNSResult of AGM
14th Nov 20257:01 amRNSAppointment of Non-Executive Director
14th Nov 20257:00 amRNSAGM Trading Update
6th Nov 20255:09 pmRNSDirector/PDMR Shareholding
24th Oct 20254:16 pmRNSDirector/PDMR Shareholding
23rd Oct 20255:07 pmRNSDirector/PDMR Shareholding
20th Oct 20254:09 pmRNSDirector/PDMR Shareholding
17th Oct 20257:00 amRNSNotice of AGM
7th Oct 20253:18 pmRNSDirector/PDMR Shareholding
22nd Sep 20255:01 pmRNSREPLACEMENT: Director/PDMR Shareholding
18th Sep 20257:00 amRNS-RPresentation on Engage Investor Platform
17th Sep 20254:23 pmRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSAudited results for the year ended 30 June 2025
9th Sep 202510:45 amRNSDirector/PDMR Shareholding
13th Aug 20257:00 amRNSNotice of Full-Year Results and Presentation
7th Aug 20253:05 pmRNSDirector/PDMR Shareholding
10th Jul 20254:17 pmRNSDirector/PDMR Shareholding
9th Jul 20251:05 pmRNSHolding(s) in Company
8th Jul 20254:00 pmRNSDirector/PDMR Shareholding
7th Jul 20253:11 pmRNSHolding(s) in Company
4th Jul 20257:00 amRNSDirectorate Change
4th Jul 20257:00 amRNSTrading Statement
12th Jun 20253:21 pmRNSDirector/PDMR Shareholding
10th Jun 202511:34 amRNSDirector/PDMR Shareholding
6th Jun 20257:00 amRNSHolding(s) in Company
4th Jun 20255:06 pmRNSDirector/PDMR Shareholding
3rd Jun 20257:03 amRNSTrading Update
7th May 20252:33 pmRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSDirectorate Change
8th Apr 20255:22 pmRNSDirector/PDMR Shareholding
8th Apr 20255:17 pmRNSDirector/PDMR Shareholding
6th Mar 20254:52 pmRNSDirector/PDMR Shareholding
5th Mar 20252:54 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.